News Releases

Keyword Search

Aug-06-2020
Oncternal Provides Business Update and Announces Second Quarter 2020 Financial Results
Jul-30-2020
Oncternal Therapeutics to Report Second Quarter 2020 Financial Results and Provide Business Update
Jul-27-2020
Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma
Jul-20-2020
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Jun-30-2020
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
Jun-30-2020
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
May-20-2020
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May-19-2020
Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
May-07-2020
Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
May-01-2020
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update